David J Maron

Summary

Affiliation: Vanderbilt University
Country: USA

Publications

  1. ncbi request reprint Cholesterol-lowering effect of a theaflavin-enriched green tea extract: a randomized controlled trial
    David J Maron
    Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    Arch Intern Med 163:1448-53. 2003
  2. ncbi request reprint Can pravastatin lower coronary event rate if HDL and LDL cholesterol are at low levels?
    David J Maron
    Kim Dayani Center for Health Promotion at Vanderbilt University, Nashville, TN, USA
    Nat Clin Pract Cardiovasc Med 1:18-9. 2004
  3. ncbi request reprint Is Optimal Medical Therapy as Used in the COURAGE Trial Feasible for Widespread Use?
    David J Maron
    Vanderbilt Heart and Vascular Institute, 1215 21st Ave South, MCE 5th Floor South Tower, Nashville, TN, 37232 8800, USA
    Curr Treat Options Cardiovasc Med 13:16-25. 2011
  4. doi request reprint Impact of adding ezetimibe to statin to achieve low-density lipoprotein cholesterol goal (from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation [COURAGE] trial)
    David J Maron
    Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Am J Cardiol 111:1557-62. 2013
  5. doi request reprint Is cardiac catheterization necessary before initial management of patients with stable ischemic heart disease? Results from a Web-based survey of cardiologists
    David J Maron
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
    Am Heart J 162:1034-1043.e13. 2011
  6. doi request reprint Impact of metabolic syndrome and diabetes on prognosis and outcomes with early percutaneous coronary intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial
    David J Maron
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    J Am Coll Cardiol 58:131-7. 2011
  7. doi request reprint Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial
    David J Maron
    Departments of Medicine and Emergency Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 8800, USA
    J Am Coll Cardiol 55:1348-58. 2010
  8. doi request reprint Impact of an initial strategy of medical therapy without percutaneous coronary intervention in high-risk patients from the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial
    David J Maron
    Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Am J Cardiol 104:1055-62. 2009
  9. ncbi request reprint Health-risk appraisal with or without disease management for worksite cardiovascular risk reduction
    David J Maron
    Division of Cardiovascular Medicine, Vanderbilt University School of Medicine, and Medical Director, Dayani Center for Health and Wellness, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    J Cardiovasc Nurs 23:513-8. 2008
  10. ncbi request reprint Flavonoids for reduction of atherosclerotic risk
    David J Maron
    Vanderbilt Page Campbell Heart Institute, Vanderbilt University Medical Center, 2311 Pierce Avenue, Nashville, TN 37232 8802, USA
    Curr Atheroscler Rep 6:73-8. 2004

Detail Information

Publications20

  1. ncbi request reprint Cholesterol-lowering effect of a theaflavin-enriched green tea extract: a randomized controlled trial
    David J Maron
    Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    Arch Intern Med 163:1448-53. 2003
    ..Our objective was to study the impact of a theaflavin-enriched green tea extract on the lipids and lipoproteins of subjects with mild to moderate hypercholesterolemia...
  2. ncbi request reprint Can pravastatin lower coronary event rate if HDL and LDL cholesterol are at low levels?
    David J Maron
    Kim Dayani Center for Health Promotion at Vanderbilt University, Nashville, TN, USA
    Nat Clin Pract Cardiovasc Med 1:18-9. 2004
  3. ncbi request reprint Is Optimal Medical Therapy as Used in the COURAGE Trial Feasible for Widespread Use?
    David J Maron
    Vanderbilt Heart and Vascular Institute, 1215 21st Ave South, MCE 5th Floor South Tower, Nashville, TN, 37232 8800, USA
    Curr Treat Options Cardiovasc Med 13:16-25. 2011
    ..Successful translation of COURAGE OMT to everyday practice will require a health care system that rewards quality of care...
  4. doi request reprint Impact of adding ezetimibe to statin to achieve low-density lipoprotein cholesterol goal (from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation [COURAGE] trial)
    David J Maron
    Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Am J Cardiol 111:1557-62. 2013
    ..In conclusion, after maximizing statin dose, the addition of ezetimibe results in a substantial increase in the percentage of patients who reach LDL cholesterol goal, a key component of optimal medical therapy...
  5. doi request reprint Is cardiac catheterization necessary before initial management of patients with stable ischemic heart disease? Results from a Web-based survey of cardiologists
    David J Maron
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
    Am Heart J 162:1034-1043.e13. 2011
    ....
  6. doi request reprint Impact of metabolic syndrome and diabetes on prognosis and outcomes with early percutaneous coronary intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial
    David J Maron
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    J Am Coll Cardiol 58:131-7. 2011
    ..Our purpose was to clarify the clinical utility of identifying metabolic syndrome (MetS) in patients with coronary artery disease (CAD)...
  7. doi request reprint Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial
    David J Maron
    Departments of Medicine and Emergency Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 8800, USA
    J Am Coll Cardiol 55:1348-58. 2010
    ..This paper describes the medical therapy used in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial and its effect on risk factors...
  8. doi request reprint Impact of an initial strategy of medical therapy without percutaneous coronary intervention in high-risk patients from the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial
    David J Maron
    Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Am J Cardiol 104:1055-62. 2009
    ..6 years or worse angina at 1 year, but it was associated with a high rate of crossover to revascularization...
  9. ncbi request reprint Health-risk appraisal with or without disease management for worksite cardiovascular risk reduction
    David J Maron
    Division of Cardiovascular Medicine, Vanderbilt University School of Medicine, and Medical Director, Dayani Center for Health and Wellness, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    J Cardiovasc Nurs 23:513-8. 2008
    ..Our objective was to determine how the intensity of intervention after HRA affected cardiovascular risk after 1 year, comparing individual follow-up counseling with environmental supports...
  10. ncbi request reprint Flavonoids for reduction of atherosclerotic risk
    David J Maron
    Vanderbilt Page Campbell Heart Institute, Vanderbilt University Medical Center, 2311 Pierce Avenue, Nashville, TN 37232 8802, USA
    Curr Atheroscler Rep 6:73-8. 2004
    ..Although there are no recommended daily intake goals for flavonoids, the data presented provide additional rationale to eat a diet containing a variety of flavonoid-rich foods and beverages...
  11. pmc Risk stratification in acute heart failure: rationale and design of the STRATIFY and DECIDE studies
    Sean P Collins
    Vanderbilt University, Nashville, TN, USA
    Am Heart J 164:825-34. 2012
    ..Methods for identifying patients that can be sent home early are lacking. Improving the physician's ability to identify and safely manage low-risk patients is essential to avoiding unnecessary use of hospital beds...
  12. pmc A comparison of criterion standard methods to diagnose acute heart failure
    Sean P Collins
    Department of Emergency Medicine, Vanderbilt University, Nashville, TN 37232, USA
    Congest Heart Fail 18:262-71. 2012
    ..Different criterion standards identify different patients from among those being evaluated for AHFS. Researchers should consider this when choosing between the various criterion standard approaches when evaluating new index tests...
  13. doi request reprint Clinical pathway: helicopter scene STEMI protocol to facilitate long-distance transfer for primary PCI
    Robert L Huang
    Vanderbilt Heart and Vascular Institute, 1215 21st Avenue South, Nashville, TN 37232, USA
    Crit Pathw Cardiol 11:193-8. 2012
    ..Although PCI-capable hospitals have improved door-to-balloon times, many patients present to non-PCI-capable facilities and have been excluded from national quality measures...
  14. doi request reprint Therapeutic procedures for coronary vasospasm-induced polymorphic ventricular tachycardia
    William F Dresen
    Vanderbilt University Medical Center, 905 Derby Trace, Nashville, TN 37211, USA
    Ther Adv Cardiovasc Dis 6:115-21. 2012
    ..Furthermore, consideration of an implantable cardioverter defibrillator is warranted when vasospasm is complicated by lethal ventricular arrhythmias...
  15. ncbi request reprint Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations
    Michael H Davidson
    Radiant Development, Chicago, Illinois, USA
    Am J Cardiol 96:556-63. 2005
    ..Most of those (75%) with cardiovascular disease in NEPTUNE II would be considered very high risk and candidates for aggressive therapy to reach the new optional treatment goals...
  16. pmc Ethnic differences in achievement of cholesterol treatment goals. Results from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology II
    Luther T Clark
    State University of New York Downstate Medical Center, Brooklyn, NY, USA
    J Gen Intern Med 21:320-6. 2006
    ..Data from the National Cholesterol Education Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey were used to assess ethnic differences in low-density lipoprotein cholesterol (LDL-C) goal achievement...
  17. ncbi request reprint Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424
    William E Boden
    VA Connecticut Healthcare System, West Haven, CT, USA
    Am Heart J 151:1173-9. 2006
    ....
  18. ncbi request reprint The evolving pattern of symptomatic coronary artery disease in the United States and Canada: baseline characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial
    William E Boden
    VA Connecticut Healthcare System, West Haven, Connecticut, USA
    Am J Cardiol 99:208-12. 2007
    ....
  19. doi request reprint Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy
    Leslee J Shaw
    Emory University School of Medicine, Atlanta, GA 30306, USA
    Circulation 117:1283-91. 2008
    ....
  20. ncbi request reprint Optimal medical therapy with or without PCI for stable coronary disease
    William E Boden
    Western New York Veterans Affairs Healthcare Network and Buffalo General Hospital SUNY, Buffalo, NY 14203, USA
    N Engl J Med 356:1503-16. 2007
    ....